Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension

References

• Xie F, Petitti DB, Chen W. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. Am J Hypertens 2005;18:464-9
   Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   Google Scholar
• Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009;53:468-70
   Google Scholar
• Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007;14:121-34
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   Google Scholar
• Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
   Google Scholar
• Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs 2001;103:417-26
   Google Scholar
• Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109:2492-9
   Google Scholar
• Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16:592-9
   Google Scholar
• Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8
   Google Scholar
• Bair TL, May HT, Prescott MF, et al. Association between baseline levels of plasma renin activity and risk of cardiovascular events. J Am Coll Cardiol 2009; 53(10 Suppl A), A383, Abstract 1028-12
   Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80
   Google Scholar
• Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005;18:13-17
   Google Scholar
• Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007;24:486-93
   Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   Google Scholar
• Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007;13(8 Suppl B):21-33
   Google Scholar
• Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9
   Google Scholar
• Chrysant SG, Murray AV, Hoppe CU, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008;24:1039-47
   Google Scholar
• Frohlich ED, Carlene Grim C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the Steering Committee, American Heart Association. Hypertension 1988;11:210-22A
   Google Scholar
• Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20
   Google Scholar
• Yarows SA, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008;25:1288-302
   Google Scholar
• Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33
   Google Scholar
• Sureshkumar KK, Vasudevan S, Marcus RJ, et al. Aliskiren: clinical experience and future perspectives of renin inhibition. Expert Opin Pharmacother 2008;9:825-37
   Google Scholar
• Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343-56
   Google Scholar
• Vaidyanathan S, Bartlett M, Dieterich HA, et al. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther 2008;26:238-46
   Google Scholar
• Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003;107:2525-7
   Google Scholar
• Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-9
   Google Scholar